Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study

Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Daudén E, Weger W, Maul JT, Naldi L, Ghislain PD, Laws PM, De Jong EMGJ, Mburu S, Koscielny V, Massana E, Sapena V, Domenech A, Kasujee I, Augustin M

Psoriasis: Targets and Therapy 2026, 16:590189

Published Date: 12 May 2026